Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Davioud-Charvet E, Delarue S, Biot C, Schwobel B, Boehme CC, Mussigbrodt A, Maes L, Sergheraert C, Grellier P, Schirmer RH and Becker K
The high-level sequence homology and structural similarity among the SLC25 transporters enable both identification of solute-binding residues and prediction of the transporting solute based on the putative chemical groups
Maintaining protein intake supports both outcomes simultaneously
Cox MM, Wendler CC, Erdelyi I, Beck A, Zeiss C, Rivkees SA
Because: patients eat less but not necessarily better and often without lifestyle restructuring The real risk We may be creating a new phenotype: Weight loss with metabolic fragility (Less overweight, but not necessarily healthier) The question is no longer: Should we prescribe GLP-1 drugs? But: What happens if patients cant stay on themand what are we not fixing underneath? Bottom line GLP-1 drugs are powerful tools
